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Abstract 
BACKGROUND: Schizophrenia is a serious disorder of the brain and mind. People with schizophrenia are at high 
risk of developing type diabetes, due to overall poor physical health, poor health care, unhealthy lifestyles, and 
side effects of antipsychotic drugs. However, atypical antipsychotics have their deficiencies, because they can be 
associated with worsening cardiovascular risk factors such as weight gain, hyperglycemia and hyperlipidemia. 
AIM: Difference in fasting blood glucose levels in people with schizophrenia between before and after receiving 
aripiprazole treatment. 
METHODS: This research was conducted in November 2017-September 2018. This research was first conducted 
in Indonesia, especially North Sumatra. This research is a numerical comparative analytical study paired with an 
experimental design approach. The number of samples is 44 people. Blood samples are taken in schizophrenia 
patients before getting the drug, before meals and before activities, assessed fasting blood glucose levels before 
being treated with aripiprazole and after drug administration for 6 weeks. Data analysis used was a paired test for 
differences in fasting blood glucose levels in people with schizophrenia between before and after receiving 
aripiprazole treatment. 
RESULTS: Based on the demographic characteristics found the research subjects based on the most age group 
were 31-40 years age group of 30 subjects (68.2%), based on the highest level of education was high school by 
26 subjects (59.1%), based on the most marital status was by status not married for 24 subjects (54.5%). It was 
found that the average blood glucose level before being given aripiprazole in schizophrenic patients was 89.23 ± 
7.13. It was found that the average blood glucose level after being given aripiprazole in schizophrenic patients 
was 86.5 ± 10.1. It was found that there were no differences in blood glucose levels before and after being given 
aripiprazole in schizophrenic patients  
CONCLUSION: There was no difference in blood glucose levels before and after being given aripiprazole in 
schizophrenic patients with p-value (0,078). 
 
 
 
 
Introduction 
 
Schizophrenia is a serious disorder of the 
brain and mind. The incidence of schizophrenia 
appears to be consistent throughout the world over 
the past half-century and targets the number of people 
with schizophrenia in Sudan who need treatment of 
around 65,517 people. The peak age of onset is 20-28 
years for men and 20-32 years for women. Onset in 
children is much rarer. The main treatment for 
schizophrenia is antipsychotic drugs, which are often 
combined with psychological and social support. 
Cardiovascular risk in psychiatric disorders is partly 
related to antipsychotic therapy [1]. 
Despite the progress of treatment in 
prevention, Cardio Vascular Disease (CVD) remains a 
leading cause of death worldwide. CVD is responsible 
for 30% of deaths and is one of the long-term health 
considerations in the overall population. CVD is also 
the most common natural cause of death in 
schizophrenia, accounting for a total of 34% of deaths 
among male patients and 31% of deaths in female 
patients and is only treated with suicide. In fact, it is 
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estimated that the prevalence of dyslipidemia, 
hypertension, obesity and diabetes type 2 is 
approximately 1.5 to 2 times higher in people with 
schizophrenia and other serious mental illnesses 
compared to the general population. Although the 
prevalence of appropriate metabolic syndrome in 
adults with schizophrenia varies greatly (between 20% 
and 60%), general estimates usually put this twice 
that of the normal population [2]. 
Cases of diabetes ketoacidosis have recently 
been reported in people with schizophrenia 
immediately after receiving treatment with 
aripiprazole. This study explores the metabolic profile 
of aripiprazole patients undergoing extensive 
metabolic follow-up, including an oral glucose 
tolerance test (OGTT), to detect abnormalities in 
glucose homeostasis [3]. 
Hert's research, at all in Liege Belgium in 
2007 reported reversibility of diabetes-related to the 
drug aripiprazole. In this study found that 74.2% (23) 
patients were taking monotherapy with aripiprazole. 
The average daily dose was 16.3 mg (SD 6.9). 
Overall, 5 patients received the highest dose of 30 
mg. All patients remained clinically stable [3]. 
However, L'Italien's and colleagues in the USA 2007 
study, aripiprazole has been marketed with an 
emphasis on metabolism with little or no increase in 
blood glucose or weight gain. The incidence of 
metabolic syndrome in patients receiving aripiprazole 
was 5.3% compared with 14.3% in patients with 
placebo [4]. 
Several studies of Reddymasu, et al., in USA 
(2008) report cases that link aripiprazole with blood 
glucose and cause weight gain [5].
 
Wani, et al., 2015 in India. Where there was a 
significant increase in fasting blood glucose levels on 
giving of aripiprazole for 14 weeks (p ˂ 0.001) [8]. 
Zhang's research in China 2014 found that 
fasting blood glucose and total cholesterol had 
significant differences between the three treatment 
groups (olanzapine, quetiapine, and aripiprazole). 
There were significant differences between the three 
treatment groups in the magnitude of changes in 
fasting glucose levels, triglycerides, and high-density 
lipoproteins. The difference in ranking in fasting 
glucose levels among the three groups found that the 
increase in the olanzapine group (mean = 94.5) was 
significantly greater than in the aripiprazole group 
(mean = 66.8) (p < 0.01). From this study, the mean 
fasting blood glucose levels at 4.65 ± 1.14 mmol/L 
and before the administration of aripiprazole were 
4.74 ± 1.74 mmol/L. From this study also found a 
mean change in fasting blood glucose levels at the 
time before aripiprazole administration of 0.08 ± 1.97 
mmol/L [7].
 
  
Racial and ethnic differences are associated 
with metabolic syndrome. Positive metabolic 
syndrome for black and white people can be 
associated with an increased risk of Cardio Vascular 
Disease (CVD), while metabolic is negative for 
Hispanics and Americans, the Philippines can be 
associated with an increased risk of diabetes. The 
possibility of differences in genotypes in the 
application of risk factors which are metabolic 
syndrome [2]. 
The Batak tribe is one of the hundreds of 
tribes found in Indonesia. Batak tribes are found in the 
North Sumatra region. There are several sub-tribes 
and hundreds of clans found in the Batak tribe. The 
Batak people themselves have tribes, among others: 
Karo, Mandailing, Simalungun, Toba, Pakpak, Angola 
and Coastal Batak [13]. 
The report on the results of Basic Health 
Research (RISKESDAS) by the Ministry of Health, 
shows that the prevalence of diabetes in Indonesia is 
6.9%. Meanwhile, if viewed based on provinces in 
Indonesia for the Province of North Sumatra, the 
prevalence of diabetes mellitus sufferers is 1.8% or 
around 160 thousand people [14]. 
According to the American Diabetes 
Association (ADA) that diabetes mellitus is associated 
with irreversible risk factors including family history, 
age and ethnicity [15]. Lifestyle is a risk factor with 
different behavioural characteristics in each tribe will 
affect the increase in the number of people with 
diabetes mellitus [16]. Batak people tend to consume 
meat and eat a lot of frequency [17].
 
So, through this research and background, I 
wanted to find out the differences in fasting blood 
glucose levels in people with Batak tribal 
schizophrenia between before and after getting 
aripiprazole treatment in Indonesia. 
 
 
Material and Methods 
 
Types of research Numerical comparative 
analysis paired with experimental research design and 
data retrieval methods with repeated measurements 
(pre-test post-test) without a control group, to see 
differences in fasting blood sugar levels in people with 
schizophrenia tribal batak between before and after 
receiving aripiprazole treatment. 
This research was carried out at the inpatient 
installation BLUD RSJ Prof.Dr. M.Ildrem Medan on 
November 2017-September 2018. The population in 
this study were schizophrenic patients, while the 
affordable population were Schizophrenic patients at 
the Inpatient Mental Hospital Installation Prof. Dr M. 
Ildrem Medan. The sample in this study was a 
nonprobability sampling type consecutive sampling, 
namely all subjects who came and met the selection 
criteria of 44 people. 
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The researcher assessed PANSS towards the 
research subject. all research subjects (schizophrenic 
patients were collected for blood sampling using 
Glucometers). Taking blood is taken at 08.00-10.00 
WIB, before being treated with Aripiprazole. After 
administration of the drug for 6 weeks with flexible-
dose of aripiprazole, the fasting blood glucose level 
was assessed. Before taking blood, the patient is 
advised to fast for 10-12 hours. 
Data analysis analysed descriptively 
statistically. The data will then be presented in the 
form of tables and narratives according to the 
variables studied. 
Table 1: Distribution of Research Subjects Based on 
Demographic Characteristics 
Variable n % 
Age (year)   
20-30  8 18.2 
31-40  30 68.2 
41-50  6 13.6 
Education    
Primary school 6 13.6 
Junior high school 9 20.5 
Senior high school 26 59.1 
Bachelor 3 6.8 
Marital status    
Single  24 54.5 
Married 20 45.5 
 
Table 1 shows that the proportion of the age 
of schizophrenic patients is 20-30 years (18.2%), 31-
40 years (68.2%), and 41-50 years (13.6%). In the 
Ayano study in 2016, it was stated that the onset of 
schizophrenia usually occurs between late 
adolescents and mid 30 years. For men, the peak age 
is onset for the first psychotic episode in the beginning 
to mid-20 years. The proportion of education for 
schizophrenic patients is elementary school (13.6%), 
junior high school (20.5%), and high school (59.1%), 
D3/S1 (6.8%). Young Lee's study in 2010 found that 
the demographics of schizophrenia patients were 
based on education with a mean of 12.8 and a 
standard deviation of 2.9. The marital status is 
unmarried (54.5%) and married (45.5%) [7].
 
In Wani et 
al.'s research in 2015 found that from marital status, 
schizophrenic patients were not married (82%) and 
married (18%). 
Tabel 2: Fasting blood glucose levels before given aripiprazole 
in schizophrenic patients 
Variable Mean SD Minimum Maximum 
Pre FBG 89.23 7.13 76 102 
 
Table 2 shows that the blood glucose level 
score with an average of 89.23 and standard deviation 
7.13, a minimum value of 76, and a maximum value of 
102. This shows that blood glucose levels in 
schizophrenic patients do not experience interference, 
indicated by normal scores, blood glucose levels are ≤ 
125 mg/dL [3]. In the study of Wani et al., in 2015 
found a mean score of fasting blood glucose levels 
before being given Aripiprazole was 86.5 with a 
standard standard deviation of 10.62 in 50 
schizophrenics [8].  
Table 3: Fasting Blood glucose levels after being given 
aripiprazole in schizophrenic patients 
Variable Mean SD Minimum Maximum 
Post FBG 86.5 10.1 50 107 
 
Table 3 shows that the blood sugar level 
score with an average of 86.5 and a standard 
deviation of 10.1, a minimum value of 50, and a 
maximum value of 107. This shows that blood glucose 
levels in schizophrenic patients do not experience 
interference, as indicated by normal blood glucose 
levels ≤ 125 mg/dL5. In the study of Wani et al., In 
2015, the mean score of fasting blood glucose levels 
after being given aripiprazole for 6 weeks was 90.92 
with a standard deviation of 9.73 in 50 schizophrenics 
[8]. 
Table 4: Differences in fasting blood glucose levels before and 
after being given aripiprazole in schizophrenic patients 
Variable Mean SD p 
Pre 
Post 
89.23 
86.5 
7.13 
10.1 
0.078 
 
Table 4 it can be seen that there is no 
difference in blood glucose levels before and after 
being given aripiprazole in schizophrenic patients with 
p-value (0.078) > 0.05. In the study, Wani et al. 's 
research in 2015 found that there were no significant 
differences in blood glucose levels before and after 
being given aripiprazole in schizophrenic patients who 
were followed for 6 weeks [8]. 
Lee and his colleagues' study in Korea in 
2010 found that fasting blood glucose levels after 
administration of aripiprazole were no different from 
those at baseline not given aripiprazole. In this study 
found that the average dose of aripiprazole was 9.3 
mg in week 1, 12.5 mg in week 2, 17.6 mg in week 4 
and 24.7 mg at week 8. In the study, baseline blood 
glucose levels were obtained. with (mean = 96.1 and 
sd = 16.4), after administration of aripiprazole at week 
8 with (mean = 90.1 and sd = 17.1) [9]. 
 
Figure 1: Observation of mean fasting blood glucose (FBG) 
scores before and after being given aripiprazole in schizophrenic 
patients 
 
Figure 1, it can be seen that the mean total 
fasting blood glucose score in men with week 0 Batak 
schizophrenia is 89.23, the mean total FBG score in 
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men with week 1 Batak schizophrenia is 88.11, mean 
total FBG score in men with week 2 Batak 
schizophrenia was 88.52, the mean total FBG score in 
men with week-old Batak schizophrenia was 85.98, 
average total FBG score in men with Batak weeks of 
schizophrenia 4 is 89, 16, the mean total FBG score in 
men with week 5 week Batak schizophrenia is 86.95, 
the mean total FBG score in men with week 6 
schizophrenia is 86.55. 
From the graph shows a decrease in fasting 
blood glucose scores on subjects before being given 
aripiprazole and after being given aripiprazole. 
 
 
Discussion 
 
In a study by Newcomer, et al., They found 
that nondiabetic schizophrenia patients showed 
adverse effects on glucose regulation after they 
started with antipsychotic drugs, which could vary in 
severity independent of adiposity and potentially 
increase long-term cardiovascular risk [10]. 
Gupta Research et al. reported a 17% 
prevalence rate for diabetes in a review of 208 
patients with psychotic disorders who received 
antipsychotic drugs. In the study of Wani et al., there 
were 52.2% (n = 24) were pre-diabetic while 13% (n = 
6) had diabetes mellitus at the end of 14 weeks of 
follow-up. Thus, the study findings are by Gupta et al. 
(13% vs 17%) [11]. 
Hyperglycemia, in some extreme cases and 
associated with ketoacidosis or hyperosmolar coma or 
death, has been reported in patients treated with 
atypical antipsychotic drug products, including 
aripiprazole. Risk factors that may predispose patients 
to severe complications include obesity and a family 
history of diabetes. In a clinical trial with aripiprazole, 
there were no significant differences in the incidence 
rates of adverse reactions related to hyperglycemia 
(including diabetes) or laboratory values of abnormal 
glycemia compared with placebo. Appropriate risk 
estimates for adverse reactions associated with 
hyperglycemia in patients treated with aripiprazole 
and with other atypical antipsychotic drug products 
are not available to allow direct comparison. Patients 
treated with antipsychotic drug products, including 
aripiprazole, must be observed for signs and 
symptoms of hyperglycemia (such as polydipsia, 
polyuria, polyphagia and weakness) and patients with 
diabetes mellitus or with risk factors for diabetes 
mellitus should be monitored regularly to control 
glucose deterioration [12]. 
In conclusion, a total of 44 subjects of 
schizophrenic patients who were included in the study 
were at the inpatient installation of Mental Hospital, 
Prof. Dr M. Ildrem Medan in November 2017-August 
2018. 
1. Based on the demographic characteristics 
found the research subjects based on the highest age 
group were the age group 31-40 years amounting to 
30 subjects (68.2%), based on the highest level of 
education was high school by 26 subjects (59.1%), 
based on the highest marital status amounting to 24 
subjects (54.4%). 
2. It was found that the average blood glucose 
level before being given aripiprazole in schizophrenic 
patients was as large as 89,23 ± 7,13. 
3. It was found that the average blood glucose 
level after being given aripiprazole in schizophrenic 
patients was as big as 86,5 ± 10,1. 
4. It was found that there were no differences 
in blood sugar levels before and after being given 
aripiprazole in schizophrenic patients. 
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